Literature DB >> 2786434

Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes.

D M Komp1, J McNamara, P Buckley.   

Abstract

The serum of children with untreated hemophagocytic syndromes contains elevated levels (23,600 to 75,200 U/mL) of soluble interleukin-2 receptor (SIL2R) that returns toward normal with clinical improvement. These levels are in excess of levels previously reported for benign conditions. They are as high as levels reported for HTLV-1-associated adult T-cell leukemia (HATL) and hairy cell leukemia (HCL) in adults and some children with poor-prognosis non-T, non-B, acute lymphoblastic leukemia (ALL). Serum SIL-2R is a marker of disease activity that has the potential to identify infants at risk for the inherited form of the disease before the disease is clinically expressed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786434

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Evaluation of serum levels of tumour necrosis factor-alpha (TNF-alpha) and soluble IL-2 receptor (sIL-2R) and CD4, CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment.

Authors:  L A Santana-Blank; M Castes; M E Rojas; F Vargas; D Scott-Algara
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

2.  Influenza A and the virus associated haemophagocytic syndrome: cluster of three cases in children with acute leukaemia.

Authors:  M N Potter; A B Foot; A Oakhill
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

Review 3.  Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management.

Authors:  Zuzana Tothova; Nancy Berliner
Journal:  J Intensive Care Med       Date:  2014-01-08       Impact factor: 3.510

4.  The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas.

Authors:  Tatsuharu Ohno; Yasunori Ueda; Ken-ichi Nagai; Takayuki Takahashi; Yoshiteru Konaka; Teruyuki Takamatsu; Takayo Suzuki; Masataka Sasada; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

5.  Delayed addition of tumor necrosis factor (TNF) antagonists inhibits the generation of CD11c+ dendritic cells derived from CD34+ cells exposed to TNF-alpha.

Authors:  Yong-Mei Guo; Makoto Hirokawa; Naoto Takahashi; Masumi Fujishima; Naohito Fujishima; Atsushi Komatsuda; Hiroyuki Tagawa; Hideaki Ohyagi; Yoshihiro Michishita; Kumi Ubukawa; Miwa Hebiguchi; Weiguo Xiao; Kenichi Sawada
Journal:  Int J Hematol       Date:  2009-12-12       Impact factor: 2.490

6.  Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state.

Authors:  S Ohga; A Ooshima; J Fukushige; K Ueda
Journal:  Eur J Pediatr       Date:  1995-07       Impact factor: 3.183

7.  The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.

Authors:  Ewa Bien; Malgorzata Rapala; Malgorzata Krawczyk; Anna Balcerska
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

8.  Familial hemophagocytic lymphohistiocytosis associated with disseminated T-cell lymphoma: a report of two siblings.

Authors:  C J Mache; I Slavc; C Schmid; G Hoefler; C E Urban; W Schwinger; E Winter; W Hulla; W Zenz; W Holter
Journal:  Ann Hematol       Date:  1994-08       Impact factor: 3.673

9.  Fulminant hemophagocytic syndrome with a high interferon gamma level diagnosed as macrophage activation syndrome.

Authors:  Tsuyoshi Muta; Yujiro Yamano
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

10.  A prospective study of CD45 isoform expression in haemophagocytic lymphohistiocytosis; an abnormal inherited immunophenotype in one family.

Authors:  R Wagner; G Morgan; S Strobel
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.